Jingfang Ju

List of Publications by Year in Descending Order

97 papers	8,406 citations	36 h-index	91 g-index
101 ext. papers	9,290 ext. citations	6.1 avg, IF	5.29 L-index

#	Paper	IF	Citations
97	Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
96	Long Non-Coding RNA GRIK1-AS1 Inhibits the Proliferation and Invasion of Gastric Cancer Cells by Regulating the miR-375/IFIT2 Axis. *Frontiers in Oncology*, **2021**, 11, 754834	5.3	
95	Development of novel microRNA-based therapeutics platform for colorectal cancer **2020**, 83-92		
94	B7-H7 is a prognostic biomarker in epithelial ovarian cancer.. *Translational Cancer Research*, **2020**, 9, 5360-5370	0.5	1
93	Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. *Molecular Therapy - Nucleic Acids*, **2020**, 19, 228-239	10.7	17
92	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. *Scientific Reports*, **2020**, 10, 14749	4.9	21
91	Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. *Cancer Letters*, **2019**, 459, 122-134	9.9	60
90	Development of microRNA-based therapy for pancreatic cancer. *Journal of Pancreatology*, **2019**, 2, 147-151	1.9	12
89	miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD. *Chemico-Biological Interactions*, **2018**, 285, 85-95	5	31
88	microRNA based prognostic biomarkers in pancreatic Cancer. *Biomarker Research*, **2018**, 6, 18	8	30
87	Development of novel miR-129 mimics with enhanced efficacy to eliminate chemoresistant colon cancer stem cells. *Oncotarget*, **2018**, 9, 8887-8897	3.3	17
86	Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1. *Oncotarget*, **2018**, 9, 2367-2383	3.3	36
85	Indole Alkaloid Derivative B, a Novel Bifunctional Agent That Mitigates 5-Fluorouracil-Induced Cardiotoxicity. *ACS Omega*, **2018**, 3, 15850-15864	3.9	5
84	Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. *Oncotarget*, **2017**, 8, 52403-52412	5.3	42
83	Autophagy regulated by miRNAs in colorectal cancer progression and resistance. *Cancer Translational Medicine*, **2017**, 3, 96-100	0.3	12
82	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
81	Transcriptomic changes associated with DKK4 overexpression in pancreatic cancer cells detected by RNA-Seq. *Tumor Biology*, **2016**, 37, 10827-38	2.9	9

80	The expanding regulatory universe of p53 in gastrointestinal cancer. *F1000Research*, **2016**, 5, 756	3.6	5
79	The emerging role of miR-506 in cancer. *Oncotarget*, **2016**, 7, 62778-62788	3.3	46
78	Reduction of gastric cancer proliferation and invasion by miR-15a mediated suppression of Bmi-1 translation. *Oncotarget*, **2016**, 7, 14522-36	3.3	36
77	Implications of Circadian Rhythm Regulation by microRNAs in Colorectal Cancer. *Cancer Translational Medicine*, **2016**, 2, 1-6	0.3	15
76	Highly stable and sensitive fluorescent probes (LysoProbes) for lysosomal labeling and tracking. *Scientific Reports*, **2015**, 5, 8576	4.9	52
75	Lysosomal targeting with stable and sensitive fluorescent probes (Superior LysoProbes): applications for lysosome labeling and tracking during apoptosis. *Scientific Reports*, **2015**, 5, 9004	4.9	56
74	Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged □55 years. *Molecular Carcinogenesis*, **2015**, 54, 281-90	5	12
73	Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. *Oncotarget*, **2015**, 6, 19735-46	3.3	103
72	Identification of miR-215 mediated targets/pathways via translational immunoprecipitation expression analysis (TrIP-chip). *Oncotarget*, **2015**, 6, 24463-73	3.3	7
71	Circulating microRNA testing for the early diagnosis and follow-up of colorectal cancer patients. *Molecular Diagnosis and Therapy*, **2014**, 18, 303-8	4.5	30
70	miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. *Cancer Letters*, **2014**, 344, 40-46	9.9	69
69	miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review). *Biomedical Reports*, **2014**, 2, 7-11	1.8	34
68	Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. *Carcinogenesis*, **2014**, 35, 760-8	4.6	31
67	miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer. *OncoTargets and Therapy*, **2014**, 7, 1481-5	4.4	17
66	Prognostic significance of miR-194 in endometrial cancer. *Biomarker Research*, **2013**, 1,	8	36
65	Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. *Journal of Gastroenterology*, **2013**, 48, 1023-33	6.9	74
64	Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. *Clinical Colorectal Cancer*, **2013**, 12, 261-6	3.8	92
63	MicroRNA: a third dimension in autophagy. *Cell Cycle*, **2013**, 12, 246-50	4.7	70

62	A frequent somatic mutation in CD274 3SUTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. *Human Mutation*, **2012**, 33, 480-4	4.7	79
61	Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms. *Blood*, **2012**, 120, 3575-85	2.2	34
60	Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. *FEBS Letters*, **2012**, 586, 2382-8	3.8	59
59	MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. *Cancer Letters*, **2012**, 320, 189-97	9.9	64
58	Biobanking and microRNA small but with great dividend. *Journal of Translational Medicine*, **2012**, 10,	8.5	1
57	Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer. *Radiation Oncology*, **2012**, 7, 114	4.2	10
56	Conversion of stationary to invasive tumor initiating cells (TICs): role of hypoxia in membrane type 1-matrix metalloproteinase (MT1-MMP) trafficking. *PLoS ONE*, **2012**, 7, e38403	3.7	15
55	Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance. *Current Enzyme Inhibition*, **2012**, 8, 118-123	0.5	6
54	Prognostic significance of miR-205 in endometrial cancer. *PLoS ONE*, **2012**, 7, e35158	3.7	77
53	Prognostic significance of miR-215 in colon cancer. *Clinical Colorectal Cancer*, **2011**, 10, 340-7	3.8	108
52	Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics. *Frontiers in Genetics*, **2011**, 2,	4.5	30
51	Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. *PLoS ONE*, **2011**, 6, e17167	3.7	85
50	Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins. *Journal of Immunotherapy*, **2011**, 34, 438-47	5	13
49	MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. *Molecular Cancer*, **2011**, 10, 99	42.1	184
48	Context-specific miRNA regulation network predicts cancer prognosis **2011**,		1
47	Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. *PLoS ONE*, **2011**, 6, e23271	3.7	57
46	Implications of miRNAs in Colorectal Cancer Chemoresistance **2011**, 2011,		8
45	A personalized microRNA microarray normalization method using a logistic regression model. *Bioinformatics*, **2010**, 26, 228-34	7.2	34

44	Translational control analysis by translationally active RNA capture/microarray analysis (TrIP-Chip). *Nucleic Acids Research*, **2010**, 38, e104	20.1	20
43	miRNAs as biomarkers in colorectal cancer diagnosis and prognosis. *Bioanalysis*, **2010**, 2, 901-6	2.1	21
42	Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. *Molecular Cancer*, **2010**, 9, 96	42.1	200
41	Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. *Breast Cancer Research*, **2010**, 12, R94	8.3	118
40	Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. *Expert Reviews in Molecular Medicine*, **2010**, 12, e33	6.7	38
39	Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 1693-706	5.6	44
38	New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. *Molecular Cancer*, **2010**, 9, 192	42.1	52
37	Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. *Clinical Cancer Research*, **2009**, 15, 7161-9	12.9	30
36	Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. *International Journal of Cancer*, **2009**, 125, 556-64	7.5	58
35	MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. *PLoS ONE*, **2009**, 4, e8445	3.7	93
34	Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. *Cancer Genomics and Proteomics*, **2009**, 6, 19-29	3.3	49
33	Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. *Experimental Cell Research*, **2008**, 314, 2110-22	4.2	65
32	Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. *Breast Cancer Research* , **2008**, 10, R22	8.3	70
31	miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. *Clinical Cancer Research*, **2008**, 14, 8080-6	12.9	134
30	The impact of genomics in understanding human melanoma progression and metastasis. *Cancer Control*, **2008**, 15, 202-15	2.2	23
29	Toward the development of chemoprevention agents (III): synthesis and anti-inflammatory activities of a new class of 5-glycylamino-2-substituted-phenyl-1,3-dioxacycloalkanes. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 1764-74	3.4	14
28	Reduction of Orc6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin. *PLoS ONE*, **2008**, 3, e4054	3.7	23
27	Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. *Cancer Genomics and Proteomics*, **2008**, 5, 1-35	3.3	9

26	Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. *Oncology Reports*, **2008**, 19, 257-62	3.5	32
25	Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. *Cancer Genomics and Proteomics*, **2008**, 5, 301-10	3.3	21
24	Design and synthesis of pentahydroxylhexylamino acids and their effect on lead decorporation. *Chemical Research in Toxicology*, **2007**, 20, 609-15	4	9
23	Investigation of miRNA Biology by Bioinformatic Tools and Impact of miRNAs in Colorectal Cancer-Regulatory Relationship of c-Myc and p53 with miRNAs. *Cancer Informatics*, **2007**, 3, 117693510700300	2.4	10
22	Toward breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified fumitremorgin C analogues. *Tetrahedron*, **2007**, 63, 5510-5528	2.4	19
21	Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted-dioxacycloalkanes. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 4775-99	3.4	10
20	Dual-acting agents that possess reversing resistance and anticancer activities: Design, synthesis, MES-SA/Dx5 cell assay, and SAR of Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3,4:1,2]pyridin[3,4-b]indol-2-substitutedacetates. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 7773-88	3.4	15
19	Toward the development of chemoprevention agents. Part II: Chemo-enzymatic synthesis and anti-inflammatory activities of a new class of 5-amino-2-substitutedphenyl-1,3-dioxacycloalkanes. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 6273-90	3.4	18
18	Cav3.1 (alpha1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2007**, 292, L833-44	5.8	23
17	Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. *Rna*, **2007**, 13, 1668-74	5.8	450
16	Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. *Clinical Cancer Research*, **2007**, 13, 4245-51	12.9	33
15	Investigation of miRNA biology by bioinformatic tools and impact of miRNAs in colorectal cancer--regulatory relationship of c-Myc and p53 with miRNAs. *Cancer Informatics*, **2007**, 3, 245-53	2.4	16
14	Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. *BMC Genomics*, **2006**, 7, 68	4.5	29
13	Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. *Clinical Cancer Research*, **2006**, 12, 2014-24	12.9	177
12	Association of insulin-like growth factor binding protein-3 expression with melanoma progression. *Molecular Cancer Therapeutics*, **2006**, 5, 3078-84	6.1	32
11	Prognostic Values of microRNAs in Colorectal Cancer. *Biomarker Insights*, **2006**, 1, 117727190600100	3.5	17
10	Novel 2-substituted nitronyl nitroxides as free radical scavengers: synthesis, biological evaluation and structure-activity relationship. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 5711-20	3.4	32
9	Synthesis and cytotoxic activities of beta-carboline amino acid ester conjugates. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 6998-7010	3.4	91

8	Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 4761-74	3.4	35
7	Prognostic Values of microRNAs in Colorectal Cancer. *Biomarker Insights*, **2006**, 2, 113-121	3.5	215
6	Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. *Cancer Genomics and Proteomics*, **2006**, 3, 317-324	3.3	138
5	Simultaneous gene expression analysis of steady-state and actively translated mRNA populations from osteosarcoma MG-63 cells in response to IL-1alpha via an open expression analysis platform. *Nucleic Acids Research*, **2003**, 31, 5157-66	20.1	17
4	An immunoprecipitation-RNA:rPCR method for the in vivo isolation of ribonucleoprotein complexes. *Methods in Molecular Biology*, **1999**, 118, 265-74	1.4	6
3	Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. *Molecular and Cellular Biology*, **1999**, 19, 1582-94	4.8	80
2	Molecular Regulation of Expression of Thymidylate Synthase **1999**, 397-408		4
1	Functional significance and therapeutic potential of miR-15a mimic in pancreatic ductal adenocarcinoma		1